Genpharmasec Share Price
Sector: Chemical Manufacturing
2.24 -0.03 (-1.32%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2.17
Today’s High
2.38
52 Week Low
1.89
52 Week High
4.32
Key Metrics
- Market Cap (In Cr) 123.48
- Beta -0.34
- Div. Yield (%) 0
- P/B 1.88
- TTM P/E 101.18
- Peg Ratio -
- Sector P/E 0
- Open Price 2.36
- Prev Close 2.27
Genpharmasec Analysis
Price Analysis
-
1 Week10.73%
-
3 Months6.57%
-
6 Month-20.07%
-
YTD-26.3%
-
1 Year-6.97%
Risk Meter
- 55% Low risk
- 55% Moderate risk
- 55% Balanced Risk
- 55% High risk
- 55% Extreme risk
Genpharmasec Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 30.41
- Selling/ General/ Admin Expenses Total
- 5.89
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 0.23
- Total Operating Expense
- 30.4
- Operating Income
- 0
- Net Income Before Taxes
- 0.25
- Net Income
- -0.13
- Diluted Normalized EPS
- 0
- Period
- 2024
- Total Assets
- 71.13
- Total Liabilities
- 6.73
- Total Equity
- 64.4
- Tangible Book Valueper Share Common Eq
- 1.21
- Period
- 2024
- Cashfrom Operating Activities
- -2.95
- Cashfrom Investing Activities
- -28.06
- Cashfrom Financing Activities
- 47.85
- Net Changein Cash
- 16.84
- Period
- 2023
- Total Revenue
- 25.52
- Selling/ General/ Admin Expenses Total
- 1.55
- Depreciation/ Amortization
- 0.02
- Other Operating Expenses Total
- 0.31
- Total Operating Expense
- 25.28
- Operating Income
- 0.24
- Net Income Before Taxes
- 0.28
- Net Income
- 1.12
- Diluted Normalized EPS
- 0.02
- Period
- 2023
- Total Assets
- 19.88
- Total Liabilities
- 4.54
- Total Equity
- 15.33
- Tangible Book Valueper Share Common Eq
- 0.33
- Period
- 2023
- Cashfrom Operating Activities
- -3.23
- Cashfrom Investing Activities
- 0.54
- Cashfrom Financing Activities
- 3.08
- Net Changein Cash
- 0.39
- Period
- 2022
- Total Revenue
- 27.32
- Selling/ General/ Admin Expenses Total
- 1.09
- Depreciation/ Amortization
- 0.01
- Other Operating Expenses Total
- 0.18
- Total Operating Expense
- 27.86
- Operating Income
- -0.54
- Net Income Before Taxes
- -0.44
- Net Income
- -0.21
- Diluted Normalized EPS
- 0
- Period
- 2022
- Total Assets
- 21.65
- Total Liabilities
- 6.28
- Total Equity
- 15.37
- Tangible Book Valueper Share Common Eq
- 0.33
- Period
- 2022
- Cashfrom Operating Activities
- -2.34
- Cashfrom Investing Activities
- 0.42
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -1.93
- Period
- 2021
- Total Revenue
- 21.31
- Selling/ General/ Admin Expenses Total
- 0.74
- Depreciation/ Amortization
- 0.01
- Other Operating Expenses Total
- 0.18
- Total Operating Expense
- 20.13
- Operating Income
- 1.18
- Net Income Before Taxes
- 1.51
- Net Income
- 1.26
- Diluted Normalized EPS
- 0.03
- Period
- 2021
- Total Assets
- 27.82
- Total Liabilities
- 7.16
- Total Equity
- 20.66
- Tangible Book Valueper Share Common Eq
- 0.45
- Period
- 2021
- Cashfrom Operating Activities
- -2.13
- Cashfrom Investing Activities
- -1.41
- Cashfrom Financing Activities
- 4.5
- Net Changein Cash
- 0.96
- Period
- 2020
- Total Revenue
- 16.5
- Selling/ General/ Admin Expenses Total
- 0.54
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.07
- Total Operating Expense
- 15.85
- Operating Income
- 0.65
- Net Income Before Taxes
- 1.21
- Net Income
- 1.01
- Diluted Normalized EPS
- 0.01
- Period
- 2020
- Total Assets
- 24.76
- Total Liabilities
- 5.72
- Total Equity
- 19.03
- Tangible Book Valueper Share Common Eq
- 0.53
- Period
- 2020
- Cashfrom Operating Activities
- 1.39
- Cashfrom Investing Activities
- -4.01
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -2.62
- Period
- 2019
- Total Revenue
- 0.38
- Selling/ General/ Admin Expenses Total
- 0.4
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.06
- Total Operating Expense
- 0.46
- Operating Income
- -0.09
- Net Income Before Taxes
- 0.29
- Net Income
- 0.23
- Diluted Normalized EPS
- 0.01
- Period
- 2019
- Total Assets
- 21.63
- Total Liabilities
- 0.02
- Total Equity
- 21.61
- Tangible Book Valueper Share Common Eq
- 0.6
- Period
- 2019
- Cashfrom Operating Activities
- -6.4
- Cashfrom Investing Activities
- -10.42
- Cashfrom Financing Activities
- 21.87
- Net Changein Cash
- 5.04
- Period
- 2024-12-31
- Total Revenue
- 8.48
- Selling/ General/ Admin Expenses Total
- 0.31
- Depreciation/ Amortization
- 0.1
- Other Operating Expenses Total
- 1.01
- Total Operating Expense
- 7.85
- Operating Income
- 0.64
- Net Income Before Taxes
- 1.29
- Net Income
- 0.78
- Diluted Normalized EPS
- 0.01
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 6.03
- Selling/ General/ Admin Expenses Total
- 0.19
- Depreciation/ Amortization
- 0.3
- Other Operating Expenses Total
- 0.73
- Total Operating Expense
- 6.21
- Operating Income
- -0.17
- Net Income Before Taxes
- 0.5
- Net Income
- 0.7
- Diluted Normalized EPS
- 0.01
- Period
- 2024-09-30
- Total Assets
- 75.38
- Total Liabilities
- 9.98
- Total Equity
- 65.4
- Tangible Book Valueper Share Common Eq
- 1.23
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 4.37
- Cashfrom Investing Activities
- -18.4
- Cashfrom Financing Activities
- -0.98
- Net Changein Cash
- -15.01
- Period
- 2024-06-30
- Total Revenue
- 5.19
- Selling/ General/ Admin Expenses Total
- 0.18
- Depreciation/ Amortization
- 0.16
- Other Operating Expenses Total
- 0.69
- Total Operating Expense
- 5.17
- Operating Income
- 0.02
- Net Income Before Taxes
- 0.49
- Net Income
- 0.29
- Diluted Normalized EPS
- 0.01
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 10.2
- Selling/ General/ Admin Expenses Total
- 0.16
- Depreciation/ Amortization
- 0.03
- Other Operating Expenses Total
- 1.8
- Total Operating Expense
- 10.18
- Operating Income
- 0.02
- Net Income Before Taxes
- 0.11
- Net Income
- -0.22
- Diluted Normalized EPS
- -0.01
- Period
- 2024-03-31
- Total Assets
- 71.13
- Total Liabilities
- 6.73
- Total Equity
- 64.4
- Tangible Book Valueper Share Common Eq
- 1.21
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -2.95
- Cashfrom Investing Activities
- -28.06
- Cashfrom Financing Activities
- 47.85
- Net Changein Cash
- 16.84
- Period
- 2023-12-31
- Total Revenue
- 6.38
- Selling/ General/ Admin Expenses Total
- 0.23
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 1.15
- Total Operating Expense
- 6.37
- Operating Income
- 0.01
- Net Income Before Taxes
- 0.03
- Net Income
- 0.06
- Diluted Normalized EPS
- 0
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Genpharmasec Technical
Moving Average
SMA
- 5 Day2.14
- 10 Day2.08
- 20 Day2.11
- 50 Day2.07
- 100 Day2.42
- 300 Day2.7
Genpharmasec Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Hindprakash Industries
- 115.8
- -11.05
- -8.71
- 199.05
- 114.7
- 131.1
- Basant Agro Tech India
- 13.96
- -0.04
- -0.29
- 24.9
- 11
- 125.8
- Genpharmasec
- 2.24
- -0.03
- -1.32
- 4.32
- 1.89
- 123.48
- Resonance Specialties
- 111.66
- 5.49
- 5.17
- 117.5
- 65
- 128.9
- Daikaffil Chemicals India
- 160.1
- -5.6
- -3.38
- 281
- 83.91
- 100.08
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Hindprakash Industries
- 89.66
- 2.86
- 6.73
- 2.52
- Basant Agro Tech India
- 32.22
- 0.73
- 7.98
- 2.9
- Genpharmasec
- -
- 1.83
- 2.7
- 2.49
- Resonance Specialties
- 34.31
- 1.78
- 16.48
- 11.55
- Daikaffil Chemicals India
- -
- 9.18
- -6.07
- -16.32
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 21-May-25
- Audited Results
- 24-Mar-25
- Independent Director Meeting
- 10-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 27-Jun-24
- A.G.M.
- 24-May-24
- Audited Results
- 27-Mar-24
- Others
- 26-Mar-24
- Independent Director Meeting
- 12-Feb-24
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 23-Jul-24
- 27-Jun-24
- AGM
- 23-Sept-23
- 01-Sept-23
- AGM
- 02-Jun-23
- 09-May-23
- EGM
- 29-Sept-22
- 05-Sept-22
- AGM



- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 05-Jun-23
- 09-Jan-24
- 09-Jan-24
- 1:1
- 1
- 0.75
- Rights issue of equity shares of Re. 1/- in the ratio of 1:1 @ premium of Re. 0.75/-.